See more : Panasonic Holdings Corporation (PCRFF) Income Statement Analysis – Financial Results
Complete financial analysis of iTeos Therapeutics, Inc. (ITOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iTeos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vision Cinemas Limited (VISIONCINE.BO) Income Statement Analysis – Financial Results
- Shunfeng International Clean Energy Limited (SHUNF) Income Statement Analysis – Financial Results
- Shenyang Jinshan Energy Co., Ltd. (600396.SS) Income Statement Analysis – Financial Results
- Stem, Inc. (STEM) Income Statement Analysis – Financial Results
- W World Corp. (WWHC) Income Statement Analysis – Financial Results
iTeos Therapeutics, Inc. (ITOS)
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 12.60M | 267.63M | 344.78M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 898.00K | 813.00K | 615.00K | 535.00K | 611.00K | 505.00K |
| Gross Profit | 11.70M | 266.82M | 344.16M | -535.00K | -611.00K | -505.00K |
| Gross Profit Ratio | 92.87% | 99.70% | 99.82% | 0.00% | 0.00% | 0.00% |
| Research & Development | 113.30M | 97.36M | 59.37M | 29.90M | 19.21M | 17.19M |
| General & Administrative | 50.40M | 43.95M | 40.51M | 15.34M | 8.84M | 4.31M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.40M | 43.95M | 40.51M | 15.34M | 8.84M | 4.31M |
| Other Expenses | 0.00 | -3.26M | -10.18M | -5.93M | -4.78M | -163.00K |
| Operating Expenses | 163.70M | 138.04M | 89.69M | 39.31M | 23.27M | 17.82M |
| Cost & Expenses | 163.70M | 138.04M | 89.69M | 39.31M | 23.27M | 17.82M |
| Interest Income | 31.77M | 11.36M | 78.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.00K |
| Depreciation & Amortization | 898.00K | 813.00K | 615.00K | 535.00K | 611.00K | 505.00K |
| EBITDA | -151.10M | 148.38M | 257.08M | -37.84M | -21.72M | -17.48M |
| EBITDA Ratio | -1,199.69% | 48.72% | 74.16% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.10M | 126.32M | 244.90M | -45.24M | -28.05M | -21.50M |
| Operating Income Ratio | -1,199.69% | 47.20% | 71.03% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 42.07M | 22.41M | 11.56M | 7.15M | 5.71M | 3.46M |
| Income Before Tax | -109.03M | 148.74M | 256.46M | -38.09M | -22.34M | -18.05M |
| Income Before Tax Ratio | -865.66% | 55.58% | 74.39% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.61M | 52.08M | 41.94M | -57.00K | 119.00K | 11.00K |
| Net Income | -112.64M | 96.65M | 214.52M | -38.03M | -22.45M | -18.06M |
| Net Income Ratio | -894.34% | 36.11% | 62.22% | 0.00% | 0.00% | 0.00% |
| EPS | -3.15 | 2.72 | 6.10 | -1.09 | -0.64 | -2.40 |
| EPS Diluted | -3.15 | 2.56 | 5.68 | -1.09 | -0.64 | -2.40 |
| Weighted Avg Shares Out | 35.76M | 35.55M | 35.18M | 35.04M | 35.02M | 7.51M |
| Weighted Avg Shares Out (Dil) | 35.76M | 37.77M | 37.77M | 35.04M | 35.02M | 7.51M |
ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -87.50% and 56.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD,...
ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 278.29% and 181.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
iTeos to Present at the Cowen 42nd Annual Health Care Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
iTeos to Participate in Upcoming Investor Conferences in February
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Why iTeos Therapeutics Topped the Market Today
The stock is about to become a component of a high-profile index.
iTeos Therapeutics Set to Join S&P SmallCap 600
NEW YORK, Dec. 31, 2021 /PRNewswire/ -- iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, January 5. S&P 500 constituent Centene Corp. (NYSE:...
Why iTeos Therapeutics, Inc. (ITOS) Might be Well Poised for a Surge
iTeos Therapeutics, Inc. (ITOS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 53%: Here's is How to Trade
The consensus price target hints at a 53.3% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Source: https://incomestatements.info
Category: Stock Reports